Nanoparticles as Contrast Agents for The Diagnosis of Alzheimer’s Disease: A Systematic Review

Ulanova, Marina; Poljak, Anne; Wang, Wen; Bongers, André; Gloag, Lucy; Gooding, J. Justin; Tilley, Richard D.; Sachdev, Perminder S.; Braidy, Nady

doi:10.2217/nnm-2019-0316

Cited by 28 publications

(17 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the techniques mentioned above, PET and MRI have been the primary imaging modalities used in AD, which allow the assessment of cortical atrophy and amyloid load, respectively. Additionally, glucose metabolism has been measured using fluorodeoxyglucose-PET [125].…”

Section: In Vivo Imaging Detection Platforms Of Ad Using Plasmonic Namentioning

confidence: 99%

“…For successful identification and imaging of plaques in AD, NPs-contrast agents must be able to cross the blood-brain barrier (BBB) [127]. Furthermore, these agents should maintain colloidal stability, safely interact with organs and display effective renal or hepatic clearance to prevent accumulation and toxic effects [125].…”

Section: In Vivo Imaging Detection Platforms Of Ad Using Plasmonic Namentioning

confidence: 99%

“…In addition, the use of Gd-based small molecules [128,129] and Gd ions in NPs have been used in imaging applications [130,131]. More details about these contrast agents can be found in the interesting reviews by Ulanova et al [125] and Sharma et al [124].…”

Section: In Vivo Imaging Detection Platforms Of Ad Using Plasmonic Namentioning

confidence: 99%

See 2 more Smart Citations

Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer’s Disease

Oyarzún

Tapia-Arellano

Cabrera

et al. 2021

Sensors

View full text Add to dashboard Cite

Alzheimer’s disease (AD), considered a common type of dementia, is mainly characterized by a progressive loss of memory and cognitive functions. Although its cause is multifactorial, it has been associated with the accumulation of toxic aggregates of the amyloid-β peptide (Aβ) and neurofibrillary tangles (NFTs) of tau protein. At present, the development of highly sensitive, high cost-effective, and non-invasive diagnostic tools for AD remains a challenge. In the last decades, nanomaterials have emerged as an interesting and useful tool in nanomedicine for diagnostics and therapy. In particular, plasmonic nanoparticles are well-known to display unique optical properties derived from their localized surface plasmon resonance (LSPR), allowing their use as transducers in various sensing configurations and enhancing detection sensitivity. Herein, this review focuses on current advances in in vitro sensing techniques such as Surface-enhanced Raman scattering (SERS), Surface-enhanced fluorescence (SEF), colorimetric, and LSPR using plasmonic nanoparticles for improving the sensitivity in the detection of main biomarkers related to AD in body fluids. Additionally, we refer to the use of plasmonic nanoparticles for in vivo imaging studies in AD.

show abstract

Section: In Vivo Imaging Detection Platforms Of Ad Using Plasmonic Namentioning

confidence: 99%

Section: In Vivo Imaging Detection Platforms Of Ad Using Plasmonic Namentioning

confidence: 99%

See 1 more Smart Citation

Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer’s Disease

Oyarzún

Tapia-Arellano

Cabrera

et al. 2021

Sensors

View full text Add to dashboard Cite

show abstract

“…It is indicated that nanoparticles could be used as drug delivery tools for the treatment of neurological diseases. [10][11][12] However, the detection limit of ELISA is only 0.312 ng mL −1 (Aβ) and 0.15 ng mL −1 (Tau), which prevents its clinical application. Therefore, the development of an ultra-sensitive detection technology for Aβamyloid and Tau protein is urgently needed for the early diagnosis of AD.…”

Section: Introductionmentioning

confidence: 99%

SERS-Based Immunoassay Enhanced with Silver Probe for Selective Separation and Detection of Alzheimer’s Disease Biomarkers

Dan¹,

Yin²,

Wang³

et al. 2021

IJN

View full text Add to dashboard Cite

Purpose Developing a sensitive SERS-based method to quantitatively detect serum biomarkers (Aβ1-42 and P-Tau-181) for the early diagnosis of Alzheimer’s disease (AD). Methods In this study, a novel SERS-based sandwich immunoassay, which consists of tannin-capped silver nanoparticles and magnetic graphene oxide (Fe 3 O 4 @GOs), was developed. We firstly applied this method for the detection of protein standards in buffer solution, obtaining the regression equation. Then, its potential value on real serum samples of AD was further explored. Results The detection linear range of Aβ1-42 and P-Tau-181 protein standards were observed to range from 100 pg mL −1 to 10 fg mL −1 , 100 pg mL −1 to 1 fg mL −1 respectively. We finally explored clinical application of the proposed method in 63 serum samples. As a result, P-tau-181 differentiated AD from non-AD dementia patients (AUC = 0.770), with a more favored ROC than Aβ1-42 (AUC = 0.383). Conclusion The developed SERS-based immunoassay is successfully applied to the determination of Aβ1-42 and P-Tau-181 in human serum specimens, which provides a promising tool for the early diagnosis of AD.

show abstract

“…A variety of nanoscale drug carriers such as liposomes, polymeric nanoparticles (NPs), inorganic NPs and bio‐NPs that are designed to deliver drugs more efficiently for AD diagnosis and therapy, have been covered by previous reviews (Agrawal et al, 2017; Mukherjee et al, 2020; Rodriguez‐Otormin et al, 2019; Ulanova et al, 2020). However, these nanocarriers usually target a specific pathological factor and are insufficient to overcome the complex pathological environment of AD.…”

Section: Introductionmentioning

confidence: 99%

Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases

Zhang

Sun

Chen

et al. 2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a progressive neurodegenerative disease that affects populations around the world. Many therapeutics have been investigated for AD diagnosis and/or therapy, but the efficacy is largely limited by the poor bioavailability of drugs and by the presence of the blood–brain barrier. Recently, the development of nanomedicines enables efficient drug delivery to the brain, but the complex pathological mechanism of AD prevents them from successful treatment. As a type of advanced nanomedicine, multifunctional nanoassemblies self‐assembled from nanoscale imaging or therapeutic agents can simultaneously target multiple pathological factors, showing great potential in the diagnosis and therapy of AD. To help readers better understand this emerging field, in this review, we first introduce the pathological mechanisms and the potential drug candidates of AD, as well as the design strategies of nanoassemblies for improving AD targeting efficiency. Moreover, the progress of dynamic nanoassemblies that can diagnose and/or treat AD in response to the endogenous or exogenous stimuli will be described. Finally, we conclude with our perspectives on the future development in this field. The objective of this review is to outline the latest progress of using nanoassemblies to overcome the complex pathological environment of AD for improved diagnosis and therapy, in hopes of accelerating the future development of intelligent AD nanomedicines. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease Diagnostic Tools > in vivo Nanodiagnostics and Imaging

show abstract

Nanoparticles as Contrast Agents for The Diagnosis of Alzheimer’s Disease: A Systematic Review

Cited by 28 publications

References 125 publications

Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer’s Disease

Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer’s Disease

SERS-Based Immunoassay Enhanced with Silver Probe for Selective Separation and Detection of Alzheimer’s Disease Biomarkers

Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases

Contact Info

Product

Resources

About